Biodesix, Inc. BDSX
7.56 USD -0.74 (-8.92%)
Regular-session close
7.56 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
7.50 Day range 8.45
5.46 52-week range 30.60
- YTD
- +11.18%
- 1 year
- +16.13%
News
globenewswire.com Biodesix (BDSX) Shareholder Alert: Johnson Fistel Investigates Following Sales Force Challenges SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodesix, Inc. - BDSX NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodesix, Inc. ("Biodesix" or the "Company") (NASDAQ: BDSX). Such investors are advised to…
businesswire.com BIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 57% Share Drop NEW YORK--(BUSINESS WIRE)---- $BDSX #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ:…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodesix, Inc. - BDSX NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ: BDSX). Such investors are advised to…
globenewswire.com Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on…benzinga.com HC Wainwright & Co. Maintains Buy on Biodesix, Lowers Price Target to $34 HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $38 to $34.
benzinga.com Lake Street Maintains Buy on Biodesix, Lowers Price Target to $30 Lake Street analyst Thomas Flaten maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $40 to $30.
benzinga.com Gold Down 1%; Charter Communications Shares Fall After Q3 Results U.S. stocks gained Friday, led by Nasdaq +1.5%, as jobs beat forecasts. Gogo and JFrog surged, while DraftKings and Biodesix plunged.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Nasdaq Jumps 400 Points; US Nonfarm Payrolls Top Estimates In October U.S. stocks were mixed: Nasdaq +1.75%, S&P +0.99%, Dow -0.21%, as October jobs beat forecasts; oil rose, while global markets mostly fell.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
benzinga.com Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook Biodesix shares fall after hours following third-quarter results and revised 2026 revenue guidance.
benzinga.com Biodesix Q3 2026 Earnings Call Transcript Biodesix (NASDAQ:BDSX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est Biodesix (NASDAQ:BDSX) lowers FY2026 sales outlook from $108.000 million-$114.000 million to $101.000 million-$103.000 million vs $111.817 million estimate.
